Esther Pompe1, Camille M Moore2, Firdaus A A Mohamed Hoesein3, Pim A de Jong3, Jean-Paul Charbonnier4, MeiLan K Han5, Steven M Humphries6, Charles R Hatt7, Craig J Galbán8,9, Ed K Silverman10,11, James D Crapo12, George R Washko11, Elisabeth A Regan13, Barry Make12, Matthew Strand2, Jan-Willem J Lammers1, Eva M van Rikxoort4, David A Lynch6. 1. Imaging Department, University Medical Center Utrecht, Utrecht, the Netherlands. 2. Division of Biostatistics, Environment and Health, National Jewish Health, Denver, Colorado, United States. 3. Department of Radiology, University Medical Center Utrecht, Utrecht, the Netherlands. 4. Diagnostic Image Analysis Group, Radboud University Medical Center, Nijmegen, the Netherlands. 5. Division of Pulmonary and Critical Care, University of Michigan Health System, Ann Arbor, Michigan, United States. 6. Department of Radiology, National Jewish Health, Denver, Colorado, United States. 7. Imbio LLC, Minneapolis, Minnesota, United States. 8. Department of Radiology, University of Michigan, Ann Arbor, Michigan, United States. 9. Center for Molecular Imaging, University of Michigan, Ann Arbor, Michigan, United States. 10. Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States. 11. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States. 12. Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, National Jewish Health, Denver, Colorado, United States. 13. Division of Rheumatology, Department of Medicine, National Jewish Health, Denver, Colorado, United States.
Abstract
BACKGROUND: Little is known about factors associated with emphysema progression in cigarette smokers. We evaluated factors associated with change in emphysema and forced expiratory volume in 1 second (FEV1) in participants with and without chronic obstructive pulmonary disease (COPD). METHODS: This retrospective study included individuals participating in the COPD Genetic Epidemiology study who completed the 5-year follow-up, including inspiratory and expiratory computed tomography (CT) and spirometry. All paired CT scans were analyzed using micro-mapping, which classifies individual voxels as emphysema or functional small airway disease (fSAD). Presence and progression of emphysema and FEV1 were determined based on comparison to nonsmoker values. Logistic regression analyses were used to identify clinical parameters associated with disease progression. RESULTS: A total of 3088 participants were included with a mean ± SD age of 60.7±8.9 years, including 72 nonsmokers. In all Global initiative for chronic Obstructive Lung Disease (GOLD) stages, the presence of emphysema at baseline was associated with emphysema progression (odds ratio [OR]: GOLD 0: 4.32; preserved ratio-impaired spirometry [PRISm]; 5.73; GOLD 1: 5.16; GOLD 2: 5.69; GOLD 3/4: 5.55; all p ≤0.01). If there was no emphysema at baseline, the amount of fSAD at baseline was associated with emphysema progression (OR for 1% increase: GOLD 0: 1.06; PRISm: 1.20; GOLD 1: 1.7; GOLD 3/4: 1.08; all p ≤ 0.03).In 1735 participants without spirometric COPD, progression in emphysema occurred in 105 (6.1%) participants and only 21 (1.2%) had progression in both emphysema and FEV1. CONCLUSIONS: The presence of emphysema is an important predictor of emphysema progression. In patients without emphysema, fSAD is associated with the development of emphysema. In participants without spirometric COPD, emphysema progression occurred independently of FEV1 decline. JCOPDF
BACKGROUND: Little is known about factors associated with emphysema progression in cigarette smokers. We evaluated factors associated with change in emphysema and forced expiratory volume in 1 second (FEV1) in participants with and without chronic obstructive pulmonary disease (COPD). METHODS: This retrospective study included individuals participating in the COPD Genetic Epidemiology study who completed the 5-year follow-up, including inspiratory and expiratory computed tomography (CT) and spirometry. All paired CT scans were analyzed using micro-mapping, which classifies individual voxels as emphysema or functional small airway disease (fSAD). Presence and progression of emphysema and FEV1 were determined based on comparison to nonsmoker values. Logistic regression analyses were used to identify clinical parameters associated with disease progression. RESULTS: A total of 3088 participants were included with a mean ± SD age of 60.7±8.9 years, including 72 nonsmokers. In all Global initiative for chronic Obstructive Lung Disease (GOLD) stages, the presence of emphysema at baseline was associated with emphysema progression (odds ratio [OR]: GOLD 0: 4.32; preserved ratio-impaired spirometry [PRISm]; 5.73; GOLD 1: 5.16; GOLD 2: 5.69; GOLD 3/4: 5.55; all p ≤0.01). If there was no emphysema at baseline, the amount of fSAD at baseline was associated with emphysema progression (OR for 1% increase: GOLD 0: 1.06; PRISm: 1.20; GOLD 1: 1.7; GOLD 3/4: 1.08; all p ≤ 0.03).In 1735 participants without spirometric COPD, progression in emphysema occurred in 105 (6.1%) participants and only 21 (1.2%) had progression in both emphysema and FEV1. CONCLUSIONS: The presence of emphysema is an important predictor of emphysema progression. In patients without emphysema, fSAD is associated with the development of emphysema. In participants without spirometric COPD, emphysema progression occurred independently of FEV1 decline. JCOPDF
Authors: Prescott G Woodruff; R Graham Barr; Eugene Bleecker; Stephanie A Christenson; David Couper; Jeffrey L Curtis; Natalia A Gouskova; Nadia N Hansel; Eric A Hoffman; Richard E Kanner; Eric Kleerup; Stephen C Lazarus; Fernando J Martinez; Robert Paine; Stephen Rennard; Donald P Tashkin; MeiLan K Han Journal: N Engl J Med Date: 2016-05-12 Impact factor: 91.245
Authors: Nadia N Hansel; George R Washko; Marilyn G Foreman; MeiLan K Han; Eric A Hoffman; Dawn L DeMeo; R Graham Barr; Edwin J R Van Beek; Ella A Kazerooni; Robert A Wise; Robert H Brown; Jennifer Black-Shinn; John E Hokanson; Nicola A Hanania; Barry Make; Edwin K Silverman; James D Crapo; Mark T Dransfield Journal: COPD Date: 2013-02 Impact factor: 2.409
Authors: Wassim W Labaki; Tian Gu; Susan Murray; Charles R Hatt; Craig J Galbán; Brian D Ross; Carlos H Martinez; Jeffrey L Curtis; Eric A Hoffman; Esther Pompe; David A Lynch; Ella A Kazerooni; Fernando J Martinez; MeiLan K Han Journal: Acad Radiol Date: 2018-07-26 Impact factor: 3.173
Authors: Ilse M Boudewijn; Dirkje S Postma; Eef D Telenga; Nick H T Ten Hacken; Wim Timens; Matthijs Oudkerk; Brian D Ross; Craig J Galbán; Maarten van den Berge Journal: Eur Respir J Date: 2015-06-25 Impact factor: 16.671
Authors: Onno M Mets; Constantinus F M Buckens; Pieter Zanen; Ivana Isgum; Bram van Ginneken; Mathias Prokop; Hester A Gietema; Jan-Willem J Lammers; Rozemarijn Vliegenthart; Matthijs Oudkerk; Rob J van Klaveren; Harry J de Koning; Willem P Th M Mali; Pim A de Jong Journal: JAMA Date: 2011-10-26 Impact factor: 56.272
Authors: Jordan Alexander Zach; John D Newell; Joyce Schroeder; James R Murphy; Douglas Curran-Everett; Eric A Hoffman; Philip M Westgate; MeiLan K Han; Edwin K Silverman; James D Crapo; David A Lynch Journal: Invest Radiol Date: 2012-10 Impact factor: 6.016
Authors: Surya P Bhatt; Xavier Soler; Xin Wang; Susan Murray; Antonio R Anzueto; Terri H Beaty; Aladin M Boriek; Richard Casaburi; Gerard J Criner; Alejandro A Diaz; Mark T Dransfield; Douglas Curran-Everett; Craig J Galbán; Eric A Hoffman; James C Hogg; Ella A Kazerooni; Victor Kim; Gregory L Kinney; Amir Lagstein; David A Lynch; Barry J Make; Fernando J Martinez; Joe W Ramsdell; Rishindra Reddy; Brian D Ross; Harry B Rossiter; Robert M Steiner; Matthew J Strand; Edwin J R van Beek; Emily S Wan; George R Washko; J Michael Wells; Chris H Wendt; Robert A Wise; Edwin K Silverman; James D Crapo; Russell P Bowler; MeiLan K Han Journal: Am J Respir Crit Care Med Date: 2016-07-15 Impact factor: 21.405
Authors: Emily S Wan; Peter J Castaldi; Michael H Cho; John E Hokanson; Elizabeth A Regan; Barry J Make; Terri H Beaty; MeiLan K Han; Jeffrey L Curtis; Douglas Curran-Everett; David A Lynch; Dawn L DeMeo; James D Crapo; Edwin K Silverman Journal: Respir Res Date: 2014-08-06
Authors: Jennifer L Boes; Maria Bule; Benjamin A Hoff; Ryan Chamberlain; David A Lynch; Jadranka Stojanovska; Fernando J Martinez; Meilan K Han; Ella A Kazerooni; Brian D Ross; Craig J Galbán Journal: Tomography Date: 2015-09
Authors: Rachel N Criner; Charles R Hatt; Craig J Galbán; Ella A Kazerooni; David A Lynch; Meredith C McCormack; Richard Casaburi; Neil R MacIntyre; Barry J Make; Fernando J Martinez; Wassim W Labaki; Jeffrey L Curtis; Mei Lan K Han Journal: Respir Res Date: 2019-12-02
Authors: Fernando J Martinez; Alvar Agusti; Bartolome R Celli; MeiLan K Han; James P Allinson; Surya P Bhatt; Peter Calverley; Sanjay H Chotirmall; Badrul Chowdhury; Patrick Darken; Carla A Da Silva; Gavin Donaldson; Paul Dorinsky; Mark Dransfield; Rosa Faner; David M Halpin; Paul Jones; Jerry A Krishnan; Nicholas Locantore; Fernando D Martinez; Hana Mullerova; David Price; Klaus F Rabe; Colin Reisner; Dave Singh; Jørgen Vestbo; Claus F Vogelmeier; Robert A Wise; Ruth Tal-Singer; Jadwiga A Wedzicha Journal: Am J Respir Crit Care Med Date: 2022-02-01 Impact factor: 21.405